These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 15471827

  • 41. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
    Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S.
    Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
    [Abstract] [Full Text] [Related]

  • 42. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P.
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [Abstract] [Full Text] [Related]

  • 43. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
    Promteangtrong C, Kunawudhi A, Phadungrerk R, Iamsa-art C, Chotipanich C.
    J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
    [Abstract] [Full Text] [Related]

  • 44. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT.
    Opoka L, Szołkowska M, Podgajny Z, Kunikowska J, Barańska I, Błasińska-Przerwa K, Jakubowska L, Rudziński P, Bestry I, Roszkowski-Śliż K.
    Pneumonol Alergol Pol; 2013 Oct; 81(3):214-20. PubMed ID: 23609428
    [Abstract] [Full Text] [Related]

  • 45. Would you bet on PET? Evaluation of the significance of positive PET scan results post-microwave ablation for non-small cell lung cancer.
    Zaheer SN, Whitley JM, Thomas PA, Steinke K.
    J Med Imaging Radiat Oncol; 2015 Dec; 59(6):702-12. PubMed ID: 26041618
    [Abstract] [Full Text] [Related]

  • 46. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
    Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, Perego P, Mangioni C, Messa C, Fazio F.
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):472-9. PubMed ID: 17106701
    [Abstract] [Full Text] [Related]

  • 47. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
    Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M.
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
    [Abstract] [Full Text] [Related]

  • 48. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 49. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, Zhang J, Fu Z, Yang G, Yuan S, Yu J.
    J Nucl Med; 2007 Aug 22; 48(8):1251-8. PubMed ID: 17631554
    [Abstract] [Full Text] [Related]

  • 50. (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
    You JJ, Cline KJ, Gu CS, Pritchard KI, Dayes IS, Gulenchyn KY, Inculet RI, Dhesy-Thind SK, Freeman MA, Chan AM, Julian JA, Levine MN.
    Br J Cancer; 2015 May 26; 112(11):1737-43. PubMed ID: 25942398
    [Abstract] [Full Text] [Related]

  • 51. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.
    Kumar R, Sharma P, Kumari A, Halanaik D, Malhotra A.
    Clin Nucl Med; 2012 May 26; 37(5):431-5. PubMed ID: 22475890
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W.
    Eur J Radiol; 2010 Feb 26; 73(2):294-9. PubMed ID: 19181468
    [Abstract] [Full Text] [Related]

  • 54. 18F-FDG PET/CT for staging of penile cancer.
    Scher B, Seitz M, Reiser M, Hungerhuber E, Hahn K, Tiling R, Herzog P, Reiser M, Schneede P, Dresel S.
    J Nucl Med; 2005 Sep 26; 46(9):1460-5. PubMed ID: 16157528
    [Abstract] [Full Text] [Related]

  • 55. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
    Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, Rigo P, Bartsch P.
    Eur Respir J; 1999 Dec 26; 14(6):1376-80. PubMed ID: 10624770
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT, Lee KS, Shim SS, Choi JY, Kwon OJ, Kim H, Shim YM, Kim J, Kim S.
    Radiology; 2006 Nov 26; 241(2):501-9. PubMed ID: 16966480
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.
    J Nucl Med; 2007 Feb 26; 48(2):221-6. PubMed ID: 17268018
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.